Co-Authors
This is a "connection" page, showing publications co-authored by Francesco De Rosa and Daniele Giacobbe.
Connection Strength
1.169
-
Antiviral treatment selection for SARS-CoV-2 pneumonia. Expert Rev Respir Med. 2021 08; 15(8):985-992.
Score: 0.237
-
Incidence and Prognosis of Ventilator-Associated Pneumonia in Critically Ill Patients with COVID-19: A Multicenter Study. J Clin Med. 2021 Feb 03; 10(4).
Score: 0.232
-
Current and emerging pharmacotherapy for the treatment of infections following open-heart surgery. Expert Opin Pharmacother. 2019 04; 20(6):751-772.
Score: 0.202
-
Ceftolozane/tazobactam: place in therapy. Expert Rev Anti Infect Ther. 2018 04; 16(4):307-320.
Score: 0.190
-
Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Infect Dis Ther. 2021 Dec; 10(4):1837-1885.
Score: 0.060
-
Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Clin Microbiol Infect. 2020 Jul; 26(7):880-894.
Score: 0.055
-
Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: Clinical features, therapy and outcome from a multicenter study. J Infect. 2019 08; 79(2):130-138.
Score: 0.052
-
Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the FUNgal infections Definitions in ICU patients (FUNDICU) project. Mycoses. 2019 Apr; 62(4):310-319.
Score: 0.050
-
Management of KPC-producing Klebsiella pneumoniae infections. Clin Microbiol Infect. 2018 Feb; 24(2):133-144.
Score: 0.046
-
Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Int J Antimicrob Agents. 2018 Feb; 51(2):244-248.
Score: 0.046